Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a dual-pronged strategy to address neurological health, focusing on both a disease-modifying therapy for multiple sclerosis and a consumer product for alcohol misuse. The company is developing Lucid-MS, an investigational therapy designed to protect and potentially restore the myelin sheath in patients with multiple sclerosis, and unbuzzd, a proprietary dietary supplement aimed at supporting alcohol metabolism and reducing the effects of acute intoxication and hangovers.
Lucid-MS targets PAD2, an enzyme associated with myelin degradation. Unlike many existing MS therapies that primarily modulate the immune system, Lucid-MS aims to directly prevent and reverse the breakdown of myelin, the protective coating around nerve fibers. This mechanism of action could offer a novel approach to treating the underlying pathophysiology of MS. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial. Additionally, Quantum BioPharma is supporting the development of Lucid-MS through an imaging collaboration with Massachusetts General Hospital, which may help in assessing the therapy's effects on myelin integrity.
In parallel, Quantum BioPharma's unbuzzd is designed to support alcohol metabolism and mitigate the acute intoxicating effects and hangover symptoms. The company cites results from a randomized, placebo-controlled clinical trial that evaluated unbuzzd's efficacy. This product represents a consumer-focused approach to alcohol-related health, addressing a significant public health concern. Quantum BioPharma invented unbuzzd and has spun out its over-the-counter (OTC) version to Unbuzzd Wellness Inc. (UWI), a company led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. Importantly, Quantum BioPharma retains 100% of the rights to develop unbuzzd or similar formulations for pharmaceutical and medical uses.
The two-pronged approach underscores Quantum BioPharma's commitment to addressing neurological and metabolic disorders from multiple angles. By advancing a potential disease-modifying therapy for MS and a consumer product for alcohol misuse, the company is positioning itself to address both chronic and acute conditions. The progress of Lucid-MS through regulatory channels and the commercial rollout of unbuzzd could provide significant value to shareholders and patients alike.
The company's focus on innovative therapies is reflected in its pipeline, which includes drug candidates in different stages of development for challenging neurodegenerative and metabolic disorders. Quantum BioPharma's wholly owned subsidiary, Lucid Psycheceuticals Inc., is leading the research and development of Lucid-MS, which has shown promise in preclinical models for preventing and reversing myelin degradation.
Investors and stakeholders can stay informed about Quantum BioPharma's latest developments through the company's newsroom at https://ibn.fm/QNTM. For more information about Quantum BioPharma and its initiatives, visit the company's website. The full article on this announcement is available at https://ibn.fm/Rl89U.
